Pelin Saglam-Metiner

Pelin Saglam-Metiner

Auto-generated profile, based on publicly available information

Pelin Saglam-Metiner

Department of Bioengineering Faculty of Engineering Ege University Izmir Turkiye

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2021 in Expert Reviews in Molecular Medicine
Verified
Journal Article
Open access
PDF file
BYBurcu Yaldiz
Burcu Yaldiz
PSPelin Saglam-Metiner
Pelin Saglam-Metiner
OYOzlem Yesil-Celiktas
Ozlem Yesil-Celiktas
The central nervous system (CNS), consisting of the brain and spinal cord, regulates the mind and functions of the organs. CNS diseases, leading to changes in neurological functions in corresponding sites and causing long-term disability, represent one of the major public health issues with significant clinical and economic burdens worldwide. In particular, the abnormal changes in the extracellular matrix under various disease conditions have been demonstrated as one of the main factors that can alter normal cell function and reduce the neuroregeneration potential in damaged tissue. Decellularised extracellular matrix (dECM)-based biomaterials have been recently utilised for CNS applications, closely mimicking the native tissue. dECM retains tissue-specific components, including proteoglycan as well as structural and functional proteins. Due to their unique composition, these biomaterials can stimulate sensitive repair mechanisms associated with CNS damages. Herein, we discuss the decellularisation of the brain and spinal cord as well as recellularisation of acellular matrix and the recent progress in the utilisation of brain and spinal cord dECM.


1 September 2022 in Preparative Biochemistry & Biotechnology
Verified
Journal Article
Closed access
BGBahar Aslanbay Guler
Bahar Aslanbay Guler
PSPelin Saglam-Metiner
Pelin Saglam-Metiner
Irem DenizIrem Deniz
Irem Deniz
ZDZeliha Demirel
Zeliha Demirel
OYOzlem Yesil-Celiktas
Ozlem Yesil-Celiktas
Esra ImamogluEsra Imamoglu
Esra Imamoglu
Astaxanthin is one of the most attractive carotenoid in the cosmetic, food, pharmaceutical, and aquaculture industries due to its strong bioactive properties. Among the various sources, several algae species are considered as rich sources of astaxanthin. Downstream processing of algae involves the majority of the total processing costs. Thus, elimination of high energy involved steps is imperative to achieve cost-effective scale in industry. This study aimed to determine operation conditions for astaxanthin extraction from wet Haematococcus pluvialis using microwave-assisted extraction. The isolated astaxanthin extract was evaluated for cytotoxicity on human lung cancer cells. The microwave-assisted extraction process at 75 °C under the power of 700 Watt for 7 min gave the highest astaxanthin yield (12.24 ± 0.54 mg astaxanthin/g wet cell weight). Based on MTT cell viability and Hoechst 33342 nuclear staining assays on A549 lung cancer cells, astaxanthin inhibited cell growth in dose- and time-dependent manners, where IC50 value was determined as 111.8 ± 14.8 µg/mL and apoptotic bodies were observed along with positive control group at 72 hr. These results showed that the treatment with astaxanthin extracted from wet H. pluvialis by microwave-assisted extraction exhibited anti-cancer activity on lung cancer cells indicating a newly potential to be utilized in industry.

3 October 2019 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MAMuge Anil-Inevi
Muge Anil-Inevi
PSPelin Sağlam-Metiner
Pelin Sağlam-Metiner
EKEvrim Ceren Kabak
Evrim Ceren Kabak
SISultan Gulce IZ
Sultan Gulce IZ

5 December 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
PSPelin Saglam-Metiner
Pelin Saglam-Metiner
SYSena Yanasik
Sena Yanasik
YOYusuf Caglar Odabasi
Yusuf Caglar Odabasi
JMJennifer Modamio
Jennifer Modamio
MNMoritz Negwer
Moritz Negwer
OYOzlem Yesil-Celiktas
Ozlem Yesil-Celiktas
Propofol and midazolam are the current standard of care for prolonged sedation in Intensive Care Units (ICUs). However, the effects and mechanism of these sedatives in brain tissue are unclear. Herein, the development of an ICU patient-on-a-chip platform to elucidate those effects is reported. The humanized neural tissue compartment combines mast cells differentiated from human induced pluripotent stem cells (hiPSCs) with cerebral organoids in a three-dimensional (3D) matrix, which is covered with a membrane populated with human cerebral microvascular endothelial cells (hCMEC/D3) that separates the tissue chamber from the vascular lumen, where sedatives were infused for four days to evaluate neurotoxicity and cell-mediated immune responses. Subsequent to propofol administration, gene expressions of CD40 and TNF-α in mast cells, AIF1 in microglia and GFAP/S100B/OLIG2/MBP in macroglia were elevated, as well as NOS2, CD80, CD40, CD68, IL6 and TNF-α mediated proinflammation is noted in cerebral organoids, which resulted in higher expressions of GJB1, GABA-A and NMDAR1 in the tissue construct of the platform. Besides, midazolam administration stimulated expression of CD40 and CD203c+ reactivated mast cell proliferation and compromised BBB permeability and decreased TEER values with higher barrier disruption, whereas increased populations of CD11b+ microglia, higher expressions of GFAP/DLG4/GJB1 and GABA-A-/NMDAR1- identities, as well as glutamate related neurotoxicity and IL1B, IFNG, IFNA1, IL6 genes mediated proinflammation, resulting in increased apoptotic zones are observed in cerebral organoids. These results suggest that different sedatives cause variations in cell type activation that modulate different pathways related to neuroinflammation and neurotoxicity in the ICU patient-on-chip platform.